Table 3.
Growth inhibitory effect of CSUOH0901 on 60 human tumor cell lines. Growth inhibition of 50 % (GI50), total growth inhibition (TGI), and LC50 are listed in the table.
| Panel/Cell Line | GI50 | TGI | LC50 |
|---|---|---|---|
| Leukemia | |||
| CCRF-CEM | 4.85E-8 | > 1.00E-4 | > 1.00E-4 |
| HL-60(TB) | 2.69E-8 | 9.67E-8 | > 1.00E-4 |
| K-562 | 4.03E-8 | > 1.00E-4 | > 1.00E-4 |
| MOLT-4 | 1.63E-7 | > 1.00E-4 | > 1.00E-4 |
| RPMI-8226 | 2.90E-7 | > 1.00E-4 | |
| Non-Small Cell Lung Cancer | |||
| A549/ATCC | 2.78E-7 | 1.36E-5 | > 1.00E-4 |
| EKVX | 5.98E-7 | > 1.00E-4 | > 1.00E-4 |
| HOP-62 | 3.29E-7 | > 1.00E-4 | > 1.00E-4 |
| HOP-92 | 3.22E-6 | > 1.00E-4 | > 1.00E-4 |
| NCI-H226 | 6.86E-7 | > 1.00E-4 | > 1.00E-4 |
| NCI-H23 | 1.62E-7 | > 1.00E-4 | > 1.00E-4 |
| NCI-H322M | 4.68E-7 | > 1.00E-4 | > 1.00E-4 |
| NCI-H460 | 1.84E-7 | 7.44E-7 | > 1.00E-4 |
| NCI-H522 | 3.35E-8 | 2.40E-7 | > 1.00E-4 |
| Colon Cancer | |||
| COLO 205 | 3.18E-7 | 1.07E-6 | > 1.00E-4 |
| HCC-2998 | 1.20E-7 | 3.92E-7 | 2.97E-6 |
| HCT-116 | 7.53E-8 | 1.02E-6 | > 1.00E-4 |
| HCT-15 | 2.89E-7 | > 1.00E-4 | > 1.00E-4 |
| HT29 | 7.72E-8 | 4.19E-7 | > 1.00E-4 |
| KM12 | 8.55E-8 | 1.13E-6 | > 1.00E-4 |
| SW-620 | 1.12E-7 | > 1.00E-4 | > 1.00E-4 |
| CNS Cancer | |||
| SF-268 | 2.88E-7 | > 1.00E-4 | > 1.00E-4 |
| SF295 | 9.83E-8 | 6.26E-7 | > 1.00E-4 |
| SF539 | 1.25E-7 | > 1.00E-4 | |
| SNB-19 | 5.37E-7 | > 1.00E-4 | > 1.00E-4 |
| SNB-75 | 2.66E-7 | > 1.00E-4 | |
| U251 | 2.66E-7 | 2.19E-5 | > 1.00E-4 |
| Melanoma | |||
| LOXIMVI | 6.66E-8 | > 1.00E-4 | > 1.00E-4 |
| MALME-3M | 2.29E-7 | > 1.00E-4 | > 1.00E-4 |
| M14 | 7.57E-8 | 6.69E-7 | > 1.00E-4 |
| MDA-MB-435 | 2.85E-8 | 9.14E-8 | > 1.00E-4 |
| SK-MEL-2 | 8.97E-8 | 6.16E-7 | > 1.00E-4 |
| SK-MEL-28 | 6.92E-7 | > 1.00E-4 | > 1.00E-4 |
| SK-MEL-5 | 2.53E-7 | 1.65E-6 | 3.41E-5 |
| UACC-257 | 1.44E-7 | > 1.00E-4 | > 1.00E-4 |
| UACC-62 | 4.14E-7 | > 1.00E-4 | > 1.00E-4 |
| Ovarian Cancer | |||
| IGROV1 | 2.37E-7 | > 1.00E-4 | > 1.00E-4 |
| OVCAR-3 | 3.96E-8 | 1.66E-7 | |
| OVCAR-4 | > 1.00E-4 | > 1.00E-4 | |
| OVCAR-5 | 5.38E-7 | > 1.00E-4 | > 1.00E-4 |
| OVCAR-8 | 2.65E-7 | > 1.00E-4 | > 1.00E-4 |
| NCI/ADR-RES | 5.62E-8 | 4.07E-7 | > 1.00E-4 |
| SK-OV-3 | 2.85E-7 | > 1.00E-4 | > 1.00E-4 |
| Renal Cancer | |||
| 786-0 | 1.91E-7 | 1.11E-6 | > 1.00E-4 |
| A498 | 1.22 E-7 | 8.53E-7 | > 1.00E-4 |
| ACHN | 6.87 E-7 | > 1.00E-4 | > 1.00E-4 |
| CAKI-1 | 1.26 E-7 | > 1.00E-4 | > 1.00E-4 |
| RXF 393 | 1.28 E-7 | 4.03E-7 | > 1.00E-4 |
| SN12C | 4.72 E-7 | > 1.00E-4 | > 1.00E-4 |
| TK-10 | 3.54 E-7 | > 1.00E-4 | > 1.00E-4 |
| UO-31 | 3.95 E-7 | > 1.00E-4 | > 1.00E-4 |
| Prostate Cancer | |||
| PC-3 | 6.77E-8 | > 1.00E-4 | > 1.00E-4 |
| DU-145 | 1.59E-7 | 4.57E-7 | > 1.00E-4 |
| Breast Cancer | |||
| MCF7 | 1.20E-7 | > 1.00E-4 | > 1.00E-4 |
| MDA-MB-231/ATCC | 2.56E-7 | 9.26E-7 | > 1.00E-4 |
| HS 578T | 8.70E-8 | > 1.00E-4 | |
| BT-549 | 6.56E-7 | > 1.00E-4 | > 1.00E-4 |
| T-47D | 6.82E-7 | > 1.00E-4 | > 1.00E-4 |
| MDA-MB-468 | 1.55E-7 | 4.01E-7 | 1.99E-5 |